
Hematologic Oncology
Latest News

Video Series

Latest Videos
Shorts










Podcasts
CME Content
More News

“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.

The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.

Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.

Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.

The updated NCCN guidelines for myeloproliferative neoplasms recommend rusfertide as a Category 1 option across both low- and high-risk polycythemia vera.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

At SOHO 2026, Jasmine Zain, MD, discussed communicating the FDA’s boxed warning for secondary malignancies post–CAR T-cell therapy to patients.

The phase 3 TAK-226-3001 trial will evaluate elritercept vs epoetin alfa for anemia in lower-risk myelodysplastic syndromes.

Data from the phase 2 PARADIGM trial may support the use of less toxic, more gentle therapies for patients with acute myeloid leukemia.

Ruben Mesa, MD, discusses the FDA approval of ropeginterferon alfa-2b-njft, the first new essential thrombocythemia therapy in nearly 30 years.

Ropeginterferon alfa may play an important role in future combination strategies in essential thrombocythemia, said Ruben Mesa, MD, FACP.




























































